JP2721929B2 - Intestinal cleansing composition - Google Patents
Intestinal cleansing compositionInfo
- Publication number
- JP2721929B2 JP2721929B2 JP19211090A JP19211090A JP2721929B2 JP 2721929 B2 JP2721929 B2 JP 2721929B2 JP 19211090 A JP19211090 A JP 19211090A JP 19211090 A JP19211090 A JP 19211090A JP 2721929 B2 JP2721929 B2 JP 2721929B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- intestinal
- present
- cleaning
- erythritol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は腸管洗浄用組成物、詳しくは便秘の処置、注
腸Ｘ線検査や大腸内視鏡検査、大腸手術等の前処置等に
利用される腸管洗浄用組成物に関する。Description: FIELD OF THE INVENTION The present invention is used for intestinal lavage compositions, in particular, for the treatment of constipation, pretreatment for enema X-ray examination, colonoscopy, colon surgery, etc. The present invention relates to a composition for cleaning the intestinal tract.
従来技術とその問題点 従来、注腸Ｘ線検査や大腸内視鏡検査、大腸手術等の
前処置等は、主としてブラウン（Brown）法、即ち低残
渣、低脂肪の食餌制限と塩類下剤及び接触性下剤の投与
を行なうが、洗腸は行なわない所謂ドライ法（dry meth
od）によって行なわれてきたが、このブラウン法は、塩
類下剤が飲みにくく、急激に下痢をきたすため高齢者や
虚弱者には耐え難いこと、塩類下剤の効果をあげるため
に大量の水分を摂取しなければならず、このため心不全
患者や腎障害のある患者では受入れられないこと、Ｘ線
学的には右半結腸の清浄が難しく、残渣が残りがちであ
ること等の重大な欠点があった。2. Description of the Related Art Conventional Techniques and Problems Conventionally, pretreatments such as enema X-ray examination, colonoscopy, and colon surgery are mainly performed by Brown method, that is, dietary restriction of low residue and low fat, salt laxative and contact. A so-called dry method, in which a laxative is administered but no bowel washing is performed.
od), the Brown's method is that salt laxatives are difficult to drink and rapidly diarrhea is difficult to withstand for elderly and frail people, and a large amount of water is consumed to make salt laxatives effective. Therefore, there are serious disadvantages such as being unacceptable in patients with heart failure and patients with renal impairment, radiologically difficult to clean the right semi-colon, and residues tending to remain. .
最近、上記ブラウン法に代って、ポリエチレングリコ
ールを主成分とし、これに電解質を加えた非吸収性、非
分泌性の腸管洗浄剤の研究開発がなされ、これは米国等
で既に市販（製品名:Golytely,Colyte）されている。ま
た上記市販品を改良する研究も行なわれている〔特表昭
63-500523号公報参照〕（以下、これらの製品を「PEG-E
LS」という）。これらの洗浄剤は非吸収性、非分泌性で
あるため心不全や腎障害患者等に対しても投与適用可能
である利点を有している。しかしながら、該PEG-ELSの
洗浄効果は、前記ブラウン法における下剤とほぼ同等で
あるにすぎず、いまだ充分満足できるものではない。し
かもPEG-ELSは、その投与適用の際に生じる気泡が誤診
の原因となる難点があり、味、臭等にも問題があり、ま
たポリエチレングリコールは溶解度が低いことから服用
時の調製が困難であり、更にポリエチレングリコール
は、患者によっては腸粘膜や肛門に炎症等の副作用を引
き起こす可能性もある。Recently, research and development of a non-absorbable, non-secretory intestinal cleanser containing polyethylene glycol as a main component and an electrolyte added thereto in place of the above-mentioned Brown method have been carried out, and are already commercially available in the United States and other countries (product name: : Golytely, Colyte). Research has also been conducted to improve the above-mentioned commercial products.
(Refer to JP-A-63-500523) (hereinafter, these products are referred to as “PEG-E
LS ”). Since these detergents are non-absorbable and non-secretory, they have the advantage that they can be administered to patients with heart failure or renal impairment. However, the cleaning effect of the PEG-ELS is almost the same as that of the laxative in the Brown method, and is not yet sufficiently satisfactory. In addition, PEG-ELS has a drawback that bubbles generated at the time of its administration and application cause a misdiagnosis, has a problem in taste, odor, and the like.In addition, polyethylene glycol has a low solubility and is difficult to prepare when taken. In addition, polyethylene glycol may cause side effects such as inflammation on the intestinal mucosa and anus in some patients.
本発明者らは、上記PEG-ELSに見られる各種の欠点を
解消、是正し、より適用が容易で、しかも洗浄効果に優
れた新しい腸管洗浄剤の研究開発を目的として鋭意研究
を重ねてきた。その過程で、エリトリトール及び／又は
キシリトールを主成分としこれに特定の電解質成分の所
定量を配合してなる組成物が、実に驚くべきことに、優
れた洗浄効果を発揮し、味、臭等の点でも従来のこの種
洗浄剤に勝っており、気泡の発生もないか或いは発生し
ても速やかに消失し、またマンニトールにみられるよう
に腸内細菌で醗酵せず、診断には全く悪影響のないこと
を見出し、ここに本発明を完成するに至った。The present inventors have intensively studied for the purpose of researching and developing a new intestinal cleansing agent which eliminates and corrects various drawbacks found in the above PEG-ELS, is easier to apply, and has a superior cleaning effect. . In the process, a composition comprising erythritol and / or xylitol as a main component and a predetermined amount of a specific electrolyte component added thereto, surprisingly, exerts an excellent cleaning effect, and has a taste, an odor and the like. It is also superior to conventional detergents in this respect, and it does not produce bubbles or disappears promptly when they do, and does not ferment with intestinal bacteria as seen in mannitol, which has no adverse effect on diagnosis. It was found that there was no such material, and the present invention was completed here.
問題点を解決するための手段 即ち、本発明は下記組成範囲の成分を含有し、液剤形
態である腸管洗浄用組成物、並びに溶解時に下記組成範
囲の成分となる用時溶解剤形態である上記腸管洗浄用組
成物及び硫酸ナトリウム、塩化カリウム、塩化ナトリウ
ム及び炭酸水素ナトリウムからなる群から選ばれる電解
質を用いてなる上記腸管洗浄用組成物に係わる。Means for Solving the Problems That is, the present invention contains the components in the following composition ranges and is a liquid preparation form for intestinal tract cleaning, and the above-mentioned in-use dissolution agent form which becomes a component in the following composition range upon dissolution The present invention relates to the intestinal lavage composition comprising an intestinal lavage composition and an electrolyte selected from the group consisting of sodium sulfate, potassium chloride, sodium chloride and sodium bicarbonate.
エリトリトール及び／又はキシリトール 5.0〜35.0g/l Na+ 35〜150mEq/l K+ ５〜20mEq/l Cl- 20〜50mEq/l HCO3 - ０〜30mEq/l SO4 2- ０〜100mEq/l。Erythritol and / or xylitol 5.0~35.0g / l Na + 35~150mEq / l K + 5~20mEq / l Cl - 20~50mEq / l HCO 3 - 0~30mEq / l SO 4 2- 0~100mEq / l.
本発明の腸管洗浄用組成物は、上記特定組成を有する
ことに基づいて、優れた洗浄効果を発揮し、味、臭等点
でも服用が容易であり、気泡の発生もないか或いは発生
しても速やかに消失し、また腸内細菌でほとんど醗酵せ
ず、診断には全く悪影響がない優れた特徴を有してい
る。The composition for cleaning the intestinal tract of the present invention exhibits an excellent cleaning effect based on having the above specific composition, is easy to take even in terms of taste and odor, and does not generate or generate air bubbles. Are also rapidly eliminated, hardly fermented by intestinal bacteria, and have excellent characteristics that have no adverse effect on diagnosis.
本発明において用いられるエリトリトールは、蔗糖の
約80％の甘味を有するテトロースアルコールの一種であ
り、下式（１）の構造を有する。Erythritol used in the present invention is a kind of tetrose alcohol having a sweetness of about 80% of sucrose, and has a structure represented by the following formula (1).
また、キシリトールは、蔗糖とほぼ同程度の甘味を有
するペントースアルコールの一種であり、下式（２）の
構造を有する。 Xylitol is a type of pentose alcohol having a sweetness almost equal to that of sucrose, and has a structure represented by the following formula (2).
本発明腸管洗浄用組成物は、上記エリトリトール及び
／又はキシリトールを１当り5.0〜35.0g、好ましくは
８〜30g含有することを必須とし、これに基づいて以下
の如き優れた効果を奏し得る。即ち、エリトリトール及
びキシリトールは、両者共胃腸管にほとんど吸収され
ず、たとえ吸収されてもそのまま***されるため人体に
とって全く悪影響はない。また結腸細菌によってほとん
ど発酵されない。従って、これらは、適用される患者に
よって、例えばポリプ切除手術時に爆発を起こしたり、
鼓腸等の不快感を引起こす水素ガス等のガス状生産物等
に代謝されたり、生体に吸収される生産物に代謝される
おそれもなく、更に腸粘膜に悪影響を及ぼさない利点が
ある。加えてエリトリトールやキシリトールは、腸管の
蠕動運動によって気泡が発生しにくく、たとえ発生して
も速やかに消失するという利点を有している。これは従
来のポリエチレングリコールを用いた腸管洗浄剤におい
て克服できず、その利用による誤診の原因の一つとなっ
ていた重大な欠点を解消するものであり、この点からも
本発明の腸管洗浄用組成物は従来のこの種洗浄剤に比し
優れたものであるといえる。 The intestinal lavage composition of the present invention essentially contains 5.0 to 35.0 g, preferably 8 to 30 g of the above erythritol and / or xylitol, and based on this, can exert the following excellent effects. That is, both erythritol and xylitol are hardly absorbed in the gastrointestinal tract, and even if absorbed, they are excreted as they are, and thus have no adverse effect on the human body. It is hardly fermented by colon bacteria. Therefore, they may explode, depending on the patient to which they are applied, for example during polypectomy surgery,
There is no danger of being metabolized into gaseous products such as hydrogen gas which cause discomfort such as flatulence or metabolized into products absorbed by the living body, and further has the advantage of not adversely affecting the intestinal mucosa. In addition, erythritol and xylitol have the advantage that bubbles hardly occur due to intestinal peristalsis and even if they occur, they disappear quickly. This solves a serious drawback that could not be overcome with the conventional intestinal cleansing agent using polyethylene glycol and was one of the causes of misdiagnosis due to its use, and from this point also the intestinal cleansing composition of the present invention. It can be said that the product is superior to conventional cleaning agents of this kind.
本発明組成物は、上記エリトリトール及び／又はキシ
リトールと共に、前記した組成の特定電解質イオンの所
定量を含有することを必須とする。これらの配合は、本
発明組成物を患者に適用した際、該患者の生体より失わ
れる正味の電解質を充分に補給し、実質的に生体からの
電解質の損失を防止し、これにより組織の電解質バラン
スを維持し、正常な状態での観察を可能とするものであ
る。It is essential that the composition of the present invention contains a predetermined amount of the specific electrolyte ion having the above composition, together with the erythritol and / or xylitol. These formulations provide sufficient replenishment of the net electrolyte lost from the patient's body when the composition of the present invention is applied to the patient, substantially preventing loss of electrolyte from the body, thereby reducing tissue electrolytes. It maintains the balance and enables observation in a normal state.
上記電解質イオンの配合量は、前記した特定範囲、よ
り好ましくはNa+40〜135mEq/l、K+7〜13mEq/l、Cl-24〜
46mEq/l、HCO3 -14〜26mEq/l及びSO4 2-0〜85mEq/lから選
ばれることが重要であり、これによって上記本発明に特
有の効果を奏し得る。かかる電解質イオンを提供できる
化合物は、特に限定されるものではないが、通常硫酸ナ
トリウム、塩化カリウム、塩化ナトリウム及び炭酸水素
ナトリウムから選択されるのが好ましい。The amount of the electrolyte ion is in the above-mentioned specific range, more preferably, Na + 40 to 135 mEq / l, K + 7 to 13 mEq / l, Cl − 24 to
46mEq / l, HCO 3 - 14~26mEq / l and SO 4 2- 0~85mEq / l is important is that selected from, thereby can achieve the effect peculiar to the present invention. The compound capable of providing such an electrolyte ion is not particularly limited, but is generally preferably selected from sodium sulfate, potassium chloride, sodium chloride and sodium hydrogen carbonate.
尚、本発明組成物は、甘味無臭のエリトリトール及び
／又はキシリトールを使用しているので、ポリエチレン
グリコールを用いる市販品のように油臭味を呈すること
はなく、また硫酸ナトリウムや硫酸カリウムを配合した
時に、それらに由来する辛味やえぐ味を増長させること
もなく、むしろ之等の嫌味を隠蔽する効果があり、服用
の容易性を保証する利点がある。尚、上記硫酸ナトリウ
ムや硫酸カリウムの配合量を少なくする場合は、洗浄効
果維持のためにエリトリトール又はキシリトールの配合
量を多くするのが望ましい。Since the composition of the present invention uses sweet and odorless erythritol and / or xylitol, it does not exhibit an oily taste like a commercial product using polyethylene glycol, and contains sodium sulfate and potassium sulfate. Occasionally, it does not increase the pungent or astringent taste derived from them, but rather has the effect of concealing such unpleasant tastes, and has the advantage of guaranteeing ease of taking. When the amount of sodium sulfate or potassium sulfate is reduced, it is desirable to increase the amount of erythritol or xylitol to maintain the cleaning effect.
本発明組成物には、更に一層飲みやすさを向上させる
ために、例えばサッカリンナトリウム等の矯味剤、フル
ーツエッセンス等の適当な香料等を適宜添加配合するこ
ともできる。In order to further improve the ease of drinking, the composition of the present invention may optionally contain a flavoring agent such as saccharin sodium and a suitable flavor such as fruit essence.
本発明組成物は、例えば上記所定量範囲のエリトリト
ール及び／又はキシリトールを上記電解質混合物に溶液
を１とするに充分量の水及び必要に応じて他の添加剤
成分を加えて混和することにより液剤形態に調製するこ
とができる。該液剤は汎用されている例えばガラスバイ
アルや合成樹脂製等の適当な充填容器に充填して製品と
される。The composition of the present invention can be prepared, for example, by adding erythritol and / or xylitol in the above-mentioned predetermined amount range to the above-mentioned electrolyte mixture by adding a sufficient amount of water to make a solution of 1 and, if necessary, other additive components and mixing them. It can be prepared in the form. The liquid agent is filled into a commonly used suitable container such as a glass vial or a synthetic resin to obtain a product.
また本発明組成物は、濃縮製剤、粉末製剤等の用時溶
解剤形態等であることもできる。粉末製剤は、例えばエ
リトリトールやキシリトールと各電解質化合物の結晶と
を粉末化し、適当な薬包紙で包装することにより調製で
きる。上記用時溶解剤は、一回の服用量をその濃度が上
記液剤の範囲内になるように、水で溶解希釈して調製、
適用できる。Further, the composition of the present invention may be in the form of a dissolving agent for use such as a concentrated preparation or a powder preparation. A powder preparation can be prepared, for example, by pulverizing erythritol or xylitol and crystals of each electrolyte compound, and packaging the powder with an appropriate medicine packaging paper. The above-mentioned dissolving agent for use is prepared by dissolving and diluting a single dose with water so that the concentration is within the range of the above-mentioned liquid preparation,
Applicable.
かくして調製される本発明組成物は、腸管洗浄等の目
的で用いられる場合、これを適用すべき患者等に応じて
その適用量を適宜決定できる。該量は個人差はあるが、
一般には１日１回約1000〜3000mlを目安とすることがで
きる。その服用速度としては、通常約15〜25ml/分程度
（約0.9〜1.5l/時程度）を採用するのがよく、該服用は
通常経口であるが、これに限定されず例えば経鼻的等で
あってもよい。When the thus-prepared composition of the present invention is used for the purpose of cleaning the intestinal tract or the like, the amount to be applied can be appropriately determined according to the patient to whom the composition is to be applied. The amount varies depending on the individual,
Generally, about 1000 to 3000 ml can be used as a guide once a day. The dose is usually about 15 to 25 ml / min (about 0.9 to 1.5 l / hour). The dose is usually oral, but is not limited thereto. It may be.
また、本発明組成物は、食事と共にその適量を服用乃
至摂取させること等によって、便秘の処置等にも利用す
ることができる。The composition of the present invention can also be used for treatment of constipation or the like by taking or ingesting an appropriate amount thereof together with a meal.
実施例 以下、本発明を更に詳しく説明するため本発明腸管洗
浄用組成物の調製例を実施例として挙げ、次いでその効
果を明らかにする実験例を挙げる。Examples Hereinafter, in order to explain the present invention in more detail, preparation examples of the intestinal tract cleaning composition of the present invention will be described as examples, and then experimental examples for clarifying the effects thereof will be described.
実施例 １ エリトリトール（和光純薬社製）及びその他の各成分
を下記第１表に示す量で溶かし、撹拌、混合して、液剤
形態の本発明の腸管洗浄用組成物を調製した。Example 1 Erythritol (manufactured by Wako Pure Chemical Industries, Ltd.) and other components were dissolved in the amounts shown in Table 1 below, stirred and mixed to prepare a liquid form of the present invention for cleaning the intestinal tract of the present invention.
上記溶液の浸透圧（重量オスモル濃度）を氷点降下度
によって測定した結果は、283mOsm/lであった。 The result of measuring the osmotic pressure (osmolality) of the above solution by the degree of freezing point depression was 283 mOsm / l.
実施例 ２ 実施例１と同様にして、下記第２表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 2 In the same manner as in Example 1, the intestinal lavage composition of the present invention having the composition shown in Table 2 below was prepared.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、283mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and as a result, it was 283 mOsm / l.
実施例 ３ 実施例１と同様にして、下記第３表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 3 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 3 below was prepared.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、302mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and was found to be 302 mOsm / l.
実施例 ４ 実施例１と同様にして、下記第４表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 4 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 4 below was prepared.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、341mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and was found to be 341 mOsm / l.
実施例 ５ 実施例１と同様にして、キシリトール（エーザイ社
製）及びその他の各成分が下記第５表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 5 In the same manner as in Example 1, xylitol (manufactured by Eisai Co., Ltd.) and other components were prepared to prepare the intestinal cleaning composition of the present invention having the composition shown in Table 5 below.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、283mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and as a result, it was 283 mOsm / l.
実施例 ６ 実施例１と同様にして、下記第６表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 6 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 6 below was prepared.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、376mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and the result was 376 mOsm / l.
実施例 ７ 実施例１と同様にして、下記第７表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 7 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 7 below was prepared.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、283mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and as a result, it was 283 mOsm / l.
実施例 ８ 実施例１と同様にして、下記第８表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 8 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 8 below was prepared.
上記溶液の浸透圧を実施例１と同様にして求めた結
果、297mOsm/lであった。 The osmotic pressure of the solution was determined in the same manner as in Example 1, and as a result, it was 297 mOsm / l.
実施例 ９ 実施例１と同様にして、下記第９表に示す組成の本発
明腸管洗浄用組成物を調製した。Example 9 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 9 below was prepared.
実施例 10 実施例１と同様にして、下記第10表に示す組成の本発
明腸管洗浄用組成物を調製した。 Example 10 In the same manner as in Example 1, a composition for cleaning the intestinal tract of the present invention having the composition shown in Table 10 below was prepared.
実施例 11 エリトリトールの粉末19.94g、 Na2SO411.38g、NaHCO3 3.36g、NaCl2.92g及びKCl 1.50gの結晶を混合し、混合物を薬包紙に包み、用時溶
解用粉末製剤を調製した。 Example 11 19.94 g of erythritol powder, 11.38 g of Na 2 SO 4 , 3.36 g of NaHCO 3 , 2.92 g of NaCl, and 1.50 g of KCl were mixed, and the mixture was wrapped in a paper envelope to prepare a powder formulation for dissolution before use.
上記用時溶解粉末製剤は、以下のようにして液剤に調
製することができる。即ち、2lのボトルに水を適量入
れ、これに上記粉末製剤を加えてよく振り完全に溶解さ
せた後、水を追加して全体を2lとする。かくして、１回
服用分の液剤を調製できる。The above-mentioned powder formulation for use at the time of use can be prepared into a liquid preparation as follows. That is, an appropriate amount of water is put into a 2 liter bottle, the powder formulation is added thereto, shaken well and completely dissolved, and then water is added to make the whole 2 liter. Thus, a liquid preparation for one dose can be prepared.
実施例 12 エリトリトール40.4g、NaHCO3 3.36g、NaCl2.92g及びKCl 1.50gを水に溶かし、全体を400mlとして、濃縮液剤形態
の本発明の腸管洗浄用組成物（エリトリトール濃度:10.
1％W/V）を調製した。Example 12 40.4 g of erythritol, 3.36 g of NaHCO 3 , 2.92 g of NaCl and 1.50 g of KCl were dissolved in water to make a total of 400 ml, and the intestinal washing composition of the present invention in the form of a concentrated solution (erythritol concentration: 10.
1% W / V).
この濃縮液剤は、これを水で希釈して全体を2lとする
ことにより、１回服用分の液剤に調製できる。This concentrated liquid preparation can be prepared into a liquid preparation for a single dose by diluting it with water to make the whole 2 l.
実験例 １ 洗浄効果試験 食餌を自由摂取させた盲腸切除ラット（ウィスター系
ラット、体重約250g、１群８匹）を供試動物として用
い、各群ラットにそれぞれ本発明実施例１で調製した腸
管洗浄用組成物（本発明群Ｉ）、同２〜８で調製した各
組成物（本発明群II〜VIII）、市販の腸管洗浄剤（下記
第11表、比較群Ｉ）並びに特表昭63-500523号公報中、
実施例３に記載の腸管洗浄剤（下記第12表、比較群II）
を、それぞれ20ml/kg/回の割合で10分間隔で８回経口投
与した。EXPERIMENTAL EXAMPLE 1 Cleaning Effect Test Intestinal tracts prepared in Example 1 of the present invention were used as test animals using cecal resected rats (Wistar rats, body weight: about 250 g, 8 animals per group) fed food freely. Cleaning compositions (Inventive group I), compositions prepared in 2 to 8 (Inventive groups II to VIII), commercially available intestinal cleansing agents (Table 11 below, Comparative group I) and Tokuyo Sho 63 -500523,
Intestinal cleansing agent described in Example 3 (Table 12 below, Comparative Group II)
Was orally administered at a rate of 20 ml / kg / time eight times at 10-minute intervals.
尚、対照群として何らの洗浄剤（組成物）をも投与し
ない非投与ラット群を設けた。 In addition, a non-administered rat group to which no detergent (composition) was administered was provided as a control group.
各群ラットにつき、投与終了から水様便及び軟便***
までの時間（***終了時迄の時間）を測定し、これを各
洗浄剤試料の即効性の指標とした。For each group of rats, the time from the end of administration to excretion of watery stools and loose stool (time until the end of excretion) was measured, and this was used as an index of the immediate effect of each detergent sample.
また、上記投与終了の２時間後に、ネンブタール麻酔
下で各群ラットを屠殺し、それらの消化管（胃〜腸）内
容物を生理食塩水で洗いだした。洗液を遠心分離（3000
rpm×５分）し、残渣を60℃で５日間乾燥させた後、各
重量を測定して消化管内容物乾燥重量とした。Two hours after the completion of the administration, the rats of each group were sacrificed under Nembutal anesthesia, and the contents of their digestive tract (stomach to intestine) were washed with physiological saline. Centrifuge the washing solution (3000
After the residue was dried at 60 ° C. for 5 days, each weight was measured and defined as the dry weight of the contents of the digestive tract.
得られた結果を第１図（消化管内容物乾燥重量）及び
第２図（水様便***までの時間）に示す。The results obtained are shown in FIG. 1 (dry weight of gastrointestinal tract contents) and FIG. 2 (time to excretion of aqueous stool).
各図におけるプロットは各群ラット総合の平均値を示
し、第１図における該値の＊印は、対照群に対してｐ＜
0.05を、＊＊印は同ｐ＜0.01をそれぞれ示す。The plot in each figure shows the average value of the rats in each group, and the asterisk of the value in FIG.
0.05 and ** indicate p <0.01, respectively.
第１図及び第２図より、本発明組成物は、市販品と比
べて腸洗浄効果及び即効性の点において優れたものであ
ることが判る。From FIG. 1 and FIG. 2, it can be seen that the composition of the present invention is superior in terms of intestinal cleansing effect and immediate effect as compared with commercial products.
第１図は本発明実験例１に従う消化管内洗浄試験による
消化管内容物乾燥重量を示すグラフであり、第２図は同
試験における水様便***までの時間を求めたグラフであ
る。FIG. 1 is a graph showing the dry weight of gastrointestinal tract contents in a gastrointestinal tract washing test according to Experimental Example 1 of the present invention, and FIG. 2 is a graph showing the time required for excretion of aqueous stool in the same test.
Claims (3)
あることを特徴とする腸管洗浄用組成物。 エリトリトール及び／又はキシリトール 5.0〜35.0g/l Na+ 35〜150mEq/l K+ ５〜20mEq/l Cl- 20〜50mEq/l HCO3 - ０〜30mEq/l SO4 2- ０〜100mEq/l1. A composition for cleaning the intestinal tract, comprising components in the following composition ranges and in liquid form. Erythritol and / or xylitol 5.0~35.0g / l Na + 35~150mEq / l K + 5~20mEq / l Cl - 20~50mEq / l HCO 3 - 0~30mEq / l SO 4 2- 0~100mEq / l
なる用時溶解剤形態であることを特徴とする腸管洗浄用
組成物。2. A composition for cleaning the intestinal tract, which is in the form of a dissolving agent before use which becomes a component within the composition range described in the claim when dissolved.
リウム及び炭酸水素ナトリウムからなる群から選ばれる
電解質を用いる請求項又は記載の腸管洗浄用組成
物。3. The intestinal cleansing composition according to claim 1, wherein an electrolyte selected from the group consisting of sodium sulfate, potassium chloride, sodium chloride and sodium hydrogen carbonate is used.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2147590 | 1990-01-30 | ||
| JP2-21475 | 1990-01-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03284620A JPH03284620A (en) | 1991-12-16 |
| JP2721929B2 true JP2721929B2 (en) | 1998-03-04 |
Family
ID=12056001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19211090A Expired - Fee Related JP2721929B2 (en) | 1990-01-30 | 1990-07-19 | Intestinal cleansing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2721929B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012102799A2 (en) | 2011-01-28 | 2012-08-02 | Shaver William A | Method, composition and package for bowel cleansing |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004067037A1 (en) * | 2003-01-30 | 2006-05-18 | 味の素株式会社 | Oral intestinal environment regulator and oral normal intestinal flora breeding kit |
| WO2004087218A1 (en) * | 2003-03-31 | 2004-10-14 | Ajinomoto Co., Inc. | Agent for imporivng function of detecting lesion in digestive tract by ct colonography or mr colonography, composition for washing intestinal tract and kit or packaged article for washing intestinal tract |
| JP4572185B2 (en) | 2006-08-28 | 2010-10-27 | ミヤリサン製薬株式会社 | Gastrointestinal cleansing aid containing butyric acid bacteria and / or lactic acid bacteria |
| JPWO2011136336A1 (en) * | 2010-04-30 | 2013-07-22 | 味の素株式会社 | Solution for oral administration and composition for gastrointestinal tract imaging used for CT colonography |
| CN103237563A (en) | 2010-10-08 | 2013-08-07 | 味之素株式会社 | Liquid preparation for oral administration used in CT colonography, and composition for imaging digestive tract |
| KR101423005B1 (en) * | 2013-10-17 | 2014-07-28 | 강윤식 | Bowel Cleansing Composition |
-
1990
- 1990-07-19 JP JP19211090A patent/JP2721929B2/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012102799A2 (en) | 2011-01-28 | 2012-08-02 | Shaver William A | Method, composition and package for bowel cleansing |
| US8753618B2 (en) | 2011-01-28 | 2014-06-17 | Braintree Laboratories, Inc. | Method, composition and package for bowel cleansing |
| US9211337B2 (en) | 2011-01-28 | 2015-12-15 | Braintree Laboratories, Inc. | Method, composition and package for bowel cleansing |
| US9566300B2 (en) | 2011-01-28 | 2017-02-14 | Braintree Laboratories, Inc. | Method, composition and package for bowel cleansing |
| US10052295B2 (en) | 2011-01-28 | 2018-08-21 | William A. Shaver | Method, composition and package for bowel cleansing |
| US10596135B2 (en) | 2011-01-28 | 2020-03-24 | William A. Shaver | Method, composition and package for bowel cleansing |
| US11241404B2 (en) | 2011-01-28 | 2022-02-08 | William A. Shaver | Method, composition and package for bowel cleansing |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03284620A (en) | 1991-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6162464A (en) | Non-aqueous colonic purgative formulations | |
| JP3255641B2 (en) | Orally administered pharmaceutical composition used as gastrointestinal detergent or laxative | |
| US6946149B2 (en) | Salt solution for colon cleansing | |
| CA2241445C (en) | Non-aqueous colonic purgative formulations | |
| US5077048A (en) | Bowel lavage composition | |
| JP6655391B2 (en) | Composition comprising PEG and ascorbate | |
| US20090258090A1 (en) | Colon cleansing solution | |
| JP2016117740A (en) | Method, composition and package for bowel cleansing | |
| JP2008001724A5 (en) | ||
| US20130136806A1 (en) | Compositions for bowel cleansing and use thereof | |
| EP2322190B1 (en) | Compositions for bowel cleansing and use thereof | |
| KR20140010117A (en) | Colonoscopy - preparation | |
| JP2721929B2 (en) | Intestinal cleansing composition | |
| JP4535234B2 (en) | Intestinal cleansing preparation | |
| KR102127003B1 (en) | Colonic purgative composition comprising sulfate salts | |
| KR101981069B1 (en) | Bowel cleansing composition | |
| JP2711409B2 (en) | Intestinal cleansing composition | |
| US10617761B2 (en) | Compositions and solutions for colon cleansing | |
| JPH03206046A (en) | Composition for enteric canal wash and enteric canal wash | |
| KR20220033790A (en) | Bowel Cleansing Composition | |
| JP2527611B2 (en) | Intestinal cleansing composition | |
| CA2007387C (en) | Bowel lavage composition | |
| KR20230140488A (en) | A composition for bowel cleansing | |
| DK169122B1 (en) | Antacid preparation | |
| JPH0127043B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |